Based on these past findings, circulating IGF1 has been proposed by some as a modifiable target for AD treatment or prevention to test in trials.6 It therefore remains to be clarified as to whether IGF concentrations in circulation are a causal factor in AD etiology. This evidence concerns the gene IGF1 and Alzheimer disease.